Publicaciones en las que colabora con Pere Ginés Gibert (17)

2024

  1. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis

    Gut, Vol. 73, Núm. 7, pp. 1183-1198

2022

  1. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2276-2286.e6

  2. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

2021

  1. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation

    Journal of Gastroenterology and Hepatology (Australia), Vol. 36, Núm. 1, pp. 240-248

  2. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Journal of Hepatology, Vol. 74, Núm. 5, pp. 1097-1108

2020

  1. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF

    Journal of Hepatology, Vol. 72, Núm. 4, pp. 688-701

  2. Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009))

    Journal of Hepatology

  3. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Journal of Hepatology, Vol. 73, Núm. 4, pp. 842-854

2019

  1. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis

    Frontiers in Immunology, Vol. 10, Núm. MAR

  2. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  3. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe

    Journal of Hepatology, Vol. 70, Núm. 3, pp. 398-411

  4. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 394, Núm. 10215, pp. 2184-2196

  5. Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis

    Hepatology, Vol. 69, Núm. 4, pp. 1686-1701

2016

  1. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure

    Hepatology, Vol. 64, Núm. 4, pp. 1249-1264

2015

  1. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis

    Hepatology, Vol. 62, Núm. 1, pp. 243-252

  2. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure

    Journal of Hepatology, Vol. 62, Núm. 4, pp. 831-840

2014

  1. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

    Journal of Hepatology